MMED MiniMed Group, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 2062583 · Fiscal year ends 12/31
Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-50.0%
TTM EPS YoY-49.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-8.6%
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets23.3%
Debt / equity0.00x
Current ratio1.81x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-04-24 | FY20252025-04-25 |
|---|---|---|
| Income statement | ||
| Revenue | $3.10B | $2.71B |
| Cost of revenue | $1.42B | $1.19B |
| Gross profit | $1.68B | $1.53B |
| R&D expense | $448.00M | $436.00M |
| SG&A expense | $1.18B | $1.08B |
| Operating income | -$190.00M | -$146.00M |
| Pretax income | -$189.00M | -$147.00M |
| Income tax | $128.00M | $52.00M |
| Net income | -$333.00M | -$213.00M |
| EBITDA | -$34.00M | -$3.00M |
| EPS (basic) | -1.30 | -0.84 |
| EPS (diluted) | -1.30 | -0.84 |
| Weighted avg. shares (diluted) | 256.60M | 252.80M |
| Balance sheet | ||
| Cash & equivalents | $298.00M | $11.00M |
| Receivables | $200.00M | $570.00M |
| Inventory | $341.00M | $311.00M |
| Current assets | $1.35B | $939.00M |
| PP&E, net | $711.00M | $706.00M |
| Goodwill | $2.26B | $2.25B |
| Intangibles | $107.00M | $132.00M |
| Total assets | $4.63B | $4.20B |
| Current liabilities | $702.00M | $710.00M |
| Total liabilities | $1.02B | $871.00M |
| Shareholders' equity | $3.61B | $3.33B |
| Shares outstanding | 280.82M | 0 |
| Cash flow statement | ||
| Operating cash flow | -$197.00M | $140.00M |
| Capital expenditure | $223.00M | $193.00M |
| Free cash flow | -$420.00M | -$53.00M |
| Investing cash flow | -$233.00M | -$193.00M |
| Financing cash flow | $716.00M | $10.00M |
| Depreciation & amortization | $156.00M | $143.00M |
| Stock-based compensation | $46.00M | $41.00M |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.